Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020761 · ClinicalTrials.gov registry record · Phase 2
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
A Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 4
- Study locations
NCT00020761 is a Phase 2 study of Gastric Cancer and Esophageal Cancer that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 51 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (84% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT00020761, a Phase 2 study of Gastric Cancer and Esophageal Cancer, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining irinotecan and paclitaxel in treating patients who have metastatic or recurrent cancer of the esophagus or stomach.
Conditions Studied
Interventions
- DRUG paclitaxel
- DRUG irinotecan hydrochloride
Study Locations (4)
California
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
Oregon
- OHSU Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2000-04 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020761
The ClinicalTrials.gov registry entry for NCT00020761 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.
NCT00020761 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, Oregon.
Frequently Asked Questions
What is clinical trial NCT00020761 about?
NCT00020761 is a clinical study titled "Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining irinotecan and paclitaxel in treating patients who have met...
What is the current status of trial NCT00020761?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2000-04. Estimated completion is 2005-08.
What conditions does trial NCT00020761 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT00020761?
The interventions under investigation include: paclitaxel (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00020761?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00020761 being conducted?
This trial has 4 study locations across California, Illinois, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.